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Abstract
Background: Marfan syndrome (MFS) is an inherited connective tissue disorder 
characterized by ectopia lentis, aortic root dilation and dissection and specific skel-
etal features. Obstructive sleep apnea (OSA) in MFS has been described earlier but 
the prevalence and its relation with the cardiovascular risk is still controversial. This 
study aimed to further investigate these aspects.
Methods: In this prospective longitudinal study, we performed an attended polysom-
nography in 40 MFS patients (60% women, 37 ± 12.8 years) and evaluated several 
cardiovascular parameters through echocardiography, resting electrocardiogram, 
24 hr‐Holter monitoring and serum NT‐ProBNP measurements.
Results: We found that OSA was present in 42.5% of the patients and that higher 
body mass index was the most important factor associated with the presence of OSA. 
We observed that overweight was present in 27.5% of the patients in the whole co-
hort and in 55.6% if >40 years. Furthermore, when evaluating the impact of OSA on 
the cardiovascular system, we observed that patients with OSA tended to have higher 
systolic blood pressure, larger distal aortic diameters and a higher prevalence of ven-
tricular arrhythmia. These differences were, however, not significant after adjusting 
for confounders.
Conclusions: Our study shows a high prevalence of OSA and a high prevalence of 
overweight in MFS patients. We found some trends between OSA and cardiovascu-
lar features but we could not establish a solid association. Our study, however might 
be underpowered, and a multicenter collaborative study could be very useful to an-
swer some important open questions.
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1 |  INTRODUCTION
Marfan syndrome (MFS) (OMIM #154700) is a pleiotropic 
inherited connective tissue disorder caused by pathogenic 
variants in the fibrillin‐1 (FBN1) gene (OMIM #134797). 
Ectopia lentis and aortic dilation or dissection in combina-
tion with typical skeletal traits are the most characteristic 
features (Judge & Dietz, 2005; Loeys et al., 2010; Pyeritz, 
2018; Verstraeten, Alaerts, Van Laer, & Loeys, 2016). Other 
common findings include myopia, mitral valve prolapse, 
pneumothorax and dural ectasia (Loeys et al., 2010). Since 
aortic dissection is the leading cause of mortality in these 
patients, up until now, research in MFS has focused mainly 
on treatment of aortic dilation and prevention of dissection. 
However, with optimized management leading to increased 
survival, other cardiovascular and noncardiovascular features 
have gained relevance and deserve further study. Within the 
nonaortic cardiovascular manifestations, myocardial disease 
and ventricular arrhythmia have been described by several 
independent groups (Alpendurada et al., 2010; Aydin et 
al., 2013; De Backer et al., 2006; Hoffmann et al., 2013; 
Meijboom et al., 2005; Yetman, Bornemeier, & McCrindle, 
2003). A few risk factors for ventricular arrhythmia, like an 
enlarged left ventricle and increased levels of N‐terminal pro 
b‐type Natriuretic peptide (NT‐ProBNP) (Aydin et al., 2013; 
Hoffmann et al., 2013; Mah et al., 2018), a marker for ven-
tricular dysfunction, have been identified in some patients, 
but additional makers still need to be detected. Within the 
noncardiovascular features, obstructive sleep apnea (OSA) 
seems to be highly prevalent in MFS although the prevalence 
varies significantly depending on the cohort and the method 
used for screening (30.8% home monitoring—64% in‐hospi-
tal attended polysomnography [PSG]) (Cistulli & Sullivan, 
1993; Kohler et al., 2009; Rybczynski et al., 2010). The 
underlying cause of OSA is not well elucidated but might 
be related to specific craniofacial features and higher upper 
airway collapsibility in MFS patients (Cistulli, Gotsopoulos, 
& Sullivan, 2001; Cistulli & Sullivan, 1995; da Palma et 
al., 2015). Whether patients carrying specific variants are 
more likely to develop OSA is unknown and the role of other 
frequently associated factors like age, sex, and higher body 
mass index (BMI) has not been studied in depth.
The relation between cardiovascular risk and OSA has 
been widely studied in the general population. In non‐MFS 
subjects, individuals with OSA seem to have a higher car-
diovascular risk, showing higher prevalence of hyperten-
sion, stroke, and arrhythmia, although these findings are 
not always consistent (Bauters, Rietzschel, Hertegonne, & 
Chirinos, 2016; Cano‐Pumarega et al., 2017; Lee, Nagubadi, 
Kryger, & Mokhlesi, 2008; O'Connor et al., 2009; Peppard, 
Young, Palta, & Skatrud, 2000). The relationship between 
OSA and aortic diameters has been studied in smaller sam-
ples  but the results are inconclusive (Baguet et al., 2011; 
Cicek, Lakadamyali, Yağbasan, Sapmaz, & Müderrisoğlu, 
2011; Gaisl, Bratton, & Kohler, 2015; Meuleman et al., 2008; 
Serizawa et al., 2008). Because of the intrinsic cardiovascular 
risk of MFS patients and the seemingly high prevalence of 
OSA in this population, a few studies investigating the re-
lation of OSA and cardiovascular complications in patients 
with MFS have been done. Kohler and colleagues showed 
a linear correlation between proximal aortic growth and the 
apnea–hypopnea index (AHI), the most common parameter 
to evaluate OSA (Kohler et al., 2009). Furthermore, a reduc-
tion in aortic growth after treatment with CPAP has been 
described in several case reports (Cistulli, Wilcox, Sullivan, 
& Jeremy, 1997; Verbraecken, Paelinck, Willemen, Van de 
Heyning, & De Backer, 2003). Rybczynski et al. (2010) did 
not find, however, a significant relation between aortic dila-
tion and the AHI but they found a relation between the AHI 
and left ventricular function, mitral valve surgery and atrial 
fibrillation (Afib). These results have not yet been confirmed 
by other groups.
The aim of our study was to investigate the prevalence 
of sleep apnea in our MFS population through an overnight 
attended PSG, and to identify additional factors which could 
be associated with sleep apnea in this concrete population. 
Furthermore, we wanted to study the association between 
sleep apnea and cardiovascular features.
2 |  MATERIALS AND METHODS
2.1 | Subjects
Patients were recruited from an ongoing longitudinal study 
on cardiovascular risk factors in patients with MFS. All pa-
tients older than 12 years and known with a (likely) patho-
genic variant in the FBN1 gene, causing MFS, were invited 
to participate in the study. Of the 108 Marfan patients evalu-
ated in our institution between January 2015 and June 2016, 
89 agreed to participate. Six patients were excluded due to 
psychosocial problems (N = 5) or residency outside Belgium 
(N = 1), nine declined participation and four were excluded 
because of (desired) pregnancy. Of the 89 recruited patients, 
two were lost to follow‐up and three were already treated for 
a known sleep‐related breathing disorder (one patient was 
treated with CPAP for severe OSA, one patient was treated 
with BiPAP for hypoventilation syndrome and one patient 
had an uvulopalatopharyngoplasty for heavy snoring). Forty 
of the 84 eligible patients agreed to undergo an in‐hospital 
attended PSG. One of these was excluded from the cardio-
vascular risk analysis because he had heart transplantation 
and aortic surgery at different levels. Figure 1 shows the in-
clusion procedure.
Since only half of the patients in the original cohort ac-
cepted to undergo a PSG and to exclude selection bias, clini-
cal data of all patients (n = 84) including medical and family 
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history, medication use and smoking status was recorded. 
All medical treatment was continued. In adults (>18 years) 
the Epworth Sleepiness Scale (ESS) (Johns, 1991) and the 
STOP‐Bang (Chung, Abdullah, & Liao, 2016) questionnaire 
were used to assess a priori risk of OSA. Anthropometric 
data recording, blood pressure measurement after 10 min of 
rest and clinical investigation was performed in all patients. 
To evaluate conduction and rhythm abnormalities a standard 
12‐lead electrocardiogram (ECG) and a 24‐hr ambulatory 
ECG (AECG) (Philips DigiTrack XT®, Philips and Trillium 
Platinum TM®, Medical Forest) were performed. The min-
imum, average and maximum heart rate, number of atrial 
extrasystoles, and number of ventricular extrasystoles were 
recorded. Complex ventricular ectopy was defined when 
couplets, triplets, or (nonsustained) ventricular tachycardia 
(VT) occurred. Heart rate variability was evaluated with the 
standard deviation of the NN interval (SDNN) and the square 
root of the mean squared difference of successive NN inter-
vals (RMSSD). A standard echocardiography (Vivid S60N®, 
GE Healthcare, equipped with a 5S probe) to evaluate aortic 
diameters, valvular function and cardiac chamber dimen-
sions and function was performed according to the American 
Society of Echocardiography and the European Association 
of Cardiovascular Imaging guidelines (Evangelista et al., 
2010; Hiratzka et al., 2010; Lang et al., 2006). Patients with 
previous aortic root replacement (AoRR) were excluded 
for the analysis of the aortic sinus and ascending aorta. 
Additionally, 4.5 ml EDTA blood was drawn to measure the 
levels of NT‐ProBNP.
All patients were prospectively followed up for a mean 
period of 30 ± 7 months. During follow‐up, they underwent 
yearly physical examination, ECG and AECG, echocardiog-
raphy and NT‐proBNP measurement.
2.2 | Polysomnography
A full‐night type 1 attended PSG was performed in our 
sleep center using a digital system (Brainnet for Windows, 
Medatec, Braine‐le‐Chateau, Belgium). Recordings in-
cluded: electroencephalography, chin and left and right 
tibial electromyography, electrooculography, respiratory 
airflow through a nasal pressure transducer, pulsoximetry, 
and thoracic and abdominal respiratory inductance ple-
thysmography. All electroencephalographic and cardiores-
piratory signals were manually scored by an experienced 
sleep technician according to the 2012 guidelines of the 
American Association of Sleep Medicine (AASM Scoring 
Manual 2.0) (Berry et al., 2012).
An apnea was defined as a drop in airflow of at least 90% 
lasting at least 10s. A hypopnea was defined as an airflow re-
duction of at least 30% from baseline associated with a ≥3% 
oxygen desaturation or an arousal. Events were classified as 
obstructive, central or mixed, as defined by the AASM scor-
ing guidelines. The AHI is the total number of apneas and 
hypopneas per hr of sleep time. The usual AHI cut‐offs were 
used to classify the results as normal (AHI < 5/hr) or mild 
(5 ≥ AHI < 15/hr), moderate (15 ≥ AHI < 30/hr), and severe 
(≥30/hr) sleep apnea. Sleep apnea was defined as obstructive 
F I G U R E  1  Flowchart of the inclusion 
and exclusion procedure. Patients were 
recruited from our outpatient clinic in the 
period between January 2015 and June 
2016. Eighty‐nine patients were included 
in a prospective longitudinal study of 
cardiovascular risk in Marfan syndrome. Of 
the eligible patients 40 agreed to undergo 
an in‐hospital attended polysomnography. 
PSG, polysomnography
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if >50% of the events were obstructive (American Academy 
of Sleep Medicine Task Force, 1999).
2.3 | Genetic data
To study possible genotype–phenotype correlations, vari-
ants in the FBN1 gene were classified according to their ef-
fect on the DNA structure as missense, in‐frame, frameshift, 
nonsense, and splice‐site variants. Variants were also clas-
sified according to the expected effect at the protein level 
(Franken et al., 2015). Frameshift and nonsense variants 
not affecting exon 65 or the last 50 nucleotides of exon 
64 were considered to have a haploinsufficient (HI) effect, 
leading to the production of a reduced amount of normal 
fibrillin‐1 (derived from the nonmutated allele). The other 
frameshift and nonsense variants and all missense variants 
were considered to have a dominant negative (DN) effect, 
leading to a shorter or a structurally abnormal but stable 
protein. These predictions were confirmed by the Mutation 
Taster software (Schwarz, Cooper, Schuelke, & Seelow, 
2014). To classify the effect of the splice‐site variants we 
used the Human Splicing Finder Software (Desmet et al., 
2009), splice‐site variants causing a change in the read-
ing frame were considered as HI, while variants affecting 
splicing but not causing a change in the reading frame were 
considered as DN.
Since variants affecting exon 24–32 are considered to 
cause a more severe phenotype (Faivre et al., 2007) we specif-
ically looked at genotype–phenotype correlations in this area.
2.4 | Statistical analysis
Statistical analysis was performed using IBM SPSS 
Statistics 25 package (SPSS Inc., Chicago, IL, USA). 
Continuous variables are expressed as mean and standard 
deviation, or median and interquartile range when appro-
priate. Categorical variables are presented as number and 
percentage.
We conducted descriptive statistics using the unpaired 
sample t test, the Mann–Whitney U test, and the Fisher exact 
test. Since AHI was not normally distributed, correlation 
analysis was performed using the Spearman correlation co-
efficient for continuous variables and the phi coefficient for 
categorical variables.
We performed logistic regression analyses to identify 
variables associated with an AHI  ≥  5. Those variables 
with a p‐value  <  0.2 in univariate analysis were candi-
dates to be used in a regression model. A p‐value < 0.05 
was required for statistical significance in the final model. 
Cardiovascular outcome variables were selected from the 
univariate analysis if there was a significant difference 
between the groups with and without OSA and if these 
variables were correlated with the AHI. We conducted lin-
ear or logistic regression analyses to determine whether 
an AHI ≥ 5/hr was an independent factor associated with 
negative cardiovascular outcome. Candidate predictors for 
each outcome were identified from univariate analysis as 
previously described. AHI was adjusted for each of these 
predictors separately. We performed Kaplan–Meier sur-
vival analysis to compare the incidence of aortic and ar-
rhythmic events between the groups with and without OSA 
during the time of follow‐up.
2.5 | Ethical issues
The study was approved by the local Independent Ethics 
Committee and the Institutional Review Board of our 
hospital (Registration number: BE670201422783). All 
subjects participating in the study gave written informed 
consent.
F I G U R E  2  Prevalence of OSA in 
patients with Marfan syndrome. The dark 
grey bars represent the overall percentage 
of patients in each of the OSA categories. 
The light grey and blue bars represent the 
percentage of patients within each sex in 
each of the OSA categories. Overall the 
prevalence of OSA in MFS was 42.5% 
(33.3% in females and 56.2% in males, 
p‐value = 0.151). F, female; M, Male; OSA, 
obstructive sleep apnea
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3 |  RESULTS
3.1 | Prevalence and risk factors associated 
with OSA
Of the 84 eligible patients, 40 (60% women, mean age 
37  ±  12.8  years) agreed to have a PSG. The two adoles-
cents, aged 14 years, were included in the analysis with the 
adult population. Baseline characteristics and a comparison 
between the patients accepting and declining PSG are pre-
sented in Table S1. There were no significant differences be-
tween these two groups except for a higher ESS score in the 
group agreeing to participate in the PSG study (median 7, 
IQR 4–11 vs. median 4, IQR 2–8, p‐value = 0.029), however 
both scores fell within the normal range. Subjective sleepi-
ness, defined as an ESS score higher than 10, was present in 
29.3% of the patients in the participating group. The mean 
BMI of the PSG group was low, 21.9 ± 5.1 kg/m2, however 
we observed that 27.5% of these patients had a BMI ≥ 25 kg/
m2. This percentage was even higher (55.6%) if patients 
≥40 years were considered.
As shown in Figure 2 the majority of the patients 
(n = 23, 57.5%) had no OSA, 11 (27.5%) had mild, four 
(10%) moderate, and two (5%) severe OSA. Most events 
were of obstructive nature but 23 patients had sporadic ep-
isodes of central apnea during the investigation. Of these 
23 patients, two stood out with 36 and 37 episodes of cen-
tral apnea. Both patients had undergone AoRR, had mild 
to moderate residual aortic regurgitation but normal left 
ventricular function. SDNN and RMSSD was low in both 
patients (21 and 20 ms—reference value for age and sex: 
34 ± 12 ms (Umetani, Singer, McCraty, & Atkinson, 1998) 
and 119 and 120ms—reference value for age and sex: 
146 ± 30 (Umetani et al., 1998), respectively).
Although OSA was present in some young patients 
(the youngest at the age of 18 years), subjects with OSA 
were significantly older compared to the no‐OSA group. 
Furthermore, patients with OSA had higher BMI and lower 
Marfan systemic score (Table 1). Next to age, BMI and 
Marfan systemic score, sex had a p‐value  <  0.2 and was 
also taken into consideration for the multivariate anal-
ysis. As shown in Table 2, the association between BMI 
and OSA remained significant after adjustment for age and 
sex (OR 1.4 per BMI unit, 95% IC 1.1–1.8, p  =  0.009). 
Although age showed significant association with OSA in 
the univariate analysis (p = 0.010), this association was no 
longer significant in the adjusted model (p = 0.065). This 
model (BMI, sex and age) had a R2 of 0.625 and area under 
de curve of 0.913, showing that this could be a good model 
to identify patients at risk. Other factors such as thorax de-
formity, scoliosis, smoking status or treatment with a beta‐
blocker were not significantly correlated with the presence 
of OSA. We could also not find a genotype–phenotype 
association (Table 1). The mean STOP‐Bang score in the 
OSA group was significantly higher than in the no‐OSA 
group (2.38 ± 1.31 vs. 1.14 ± 0.91, p = 0.002). As shown 
in the Table S2, however, the diagnostic performance of 
the STOP‐Bang was weak, with a sensitivity of 47.1% and 
a positive predictive value of 80%. The ESS score was not 
different between patients with and without OSA (Table 1). 
The ESS performed even worse than the STOP‐Bang ques-
tionnaire. Adding the STOP‐Bang to the previous model 
increased the R2 to 0.644 and the area under the curve to 
0.922.
3.2 | Relation between OSA and 
cardiovascular features
Higher systolic blood pressure (p = 0.014), larger diameter 
of the descending aorta at the thoracic and abdominal lev-
els (p = 0.002 and p = 0.002, respectively) and higher prob-
ability of complex ventricular events (p = 0.011) were found 
in Marfan patients with OSA (Table 1). This difference was 
however not significant anymore after adjusting for different 
confounding variables (Table S3), being age and/or BMI the 
most important (Figure 3).
Seven patients had undergone AoRR before enrolment 
(five in the group with OSA) and were not considered for 
the analysis of the proximal aortic diameters. Although the 
mean diameter of the aortic sinus and aorta ascendens was 
higher in patients with OSA, this difference was not sig-
nificant (p  =  0.341 and p  =  0.051 respectively) (Table 1). 
Additionally, left ventricular diameter and function and 
NT‐ProBNP levels did not differ significantly between both 
groups (Table 1).
During a mean follow‐up time of 30 ± 7 months, seven 
patients had an arterial event: two women had a type A aor-
tic dissection (one at the level of the sinus of Valsalva at 
a diameter of 47 mm and one at the level of the arch after 
previous AoRR); one woman underwent elective AoRR and 
subsequently presented a type B aortic dissection; two men 
underwent elective AoRR; one woman required aortic valve 
replacement due to severe aortic valve insufficiency after 
AoRR and one woman presented spontaneous coronary ar-
tery dissection. Of these seven patients, three had mild OSA 
and one moderate OSA. Aortic root growth over the study 
period was similar between the groups (0.3  mm/year IQR 
0.30–1.5 for patients with OSA and 0.5 mm/year IQR 0–0.9 
for patients without OSA, p = 0.894). Four patients had an 
Afib episode and one patient had a sustained VT episode. 
Three of the four patients with Afib had OSA. The patient 
with sustained VT did not have OSA. We did not find a sig-
nificant higher rate of cardiovascular events in the group with 
OSA (HR 0.599, p = 0.439 for aortic events and HR 1.458, 
p = 0.227 for Afib). The two patients with severe OSA were 
treated with nasal CPAP (nCPAP) according to the standard 
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T A B L E  1  Characteristics of Marfan patients with and without OSA
  AHI < 5 (n = 23) AHI ≥ 5 (n = 17) p‐valuea
Correlation coef-
ficient b p‐valuec
General features
Age (yr) 32.1 ± 11.4 44.75 ± 14.3 0.004* 0.382 0.015*
Male (%) 7 (30.4) 9 (52.9) 0.151 −0.227 0.151
BMI (kg/m2) 19.5 ± 3.6 25.6 ± 4.5 <0.001* 0.434 0.005*
Marfan systemic scored 8.9 ± 3 6.6 ± 3.8 0.039* −0.330 0.037*
Pectus excavatum (%) 11 (47.8) 6 (37.5) 0.379 −0.102 0.522
Pectus carinatum (%) 4 (17.5) 4 (25) 0.425 0.093 0.563
Scoliosis (%) 20 (87) 10 (62.5) 0.082 −0.286 0.075
Smoking (%) 3 (13) 1 (6.3) 0.452 −0.110 0.492
Genetic data
Type of variant (DNA effect)
Missense (%) 12 (52.2) 17 (41.2) 0.491 −0.109 0.491
Frameshift (%) 4 (17.4) 6 (35.3) 0.196 0.204 0.196
Nonsense (%) 6 (26.1) 2 (11.8) 0.428 −0.177 0.263
Splice‐site (%) 1 (4.3) 1 (5.9) 1 0.035 0.826
In‐frame (%) 0 (0) 1 (5.9) 0.425 0.186 0.239
Type of variant (protein effect)
Haploinsufficient 9 (39.1) 7 (41.2) 0.896 −0.021 0.896
Localization
Within exons 24–32 4 (17.4) 3 (17.6) 1 0.003 0.983
Sleep questionnaires
ESS score 6.1 ± 3.3 9.1 ± 5.6 0.052 0.252 0.132
STOP‐bang score 1.1 ± 0.91 2.4 ± 1.31 0.002* 0.649 <0.001*
Cardiovascular features
Use of BB (%)e 16 (69.6) 11 (68.8) 0.614 −0.009 0.957
AoRR at baseline (%) 2 (8.7) 5 (31.3) 0.071 0.289 0.071
SBP (mmHg) 122.9 ± 15.0 136.2 ± 16.3 0.014* 0.469 0.003*
DBP (mmHg) 69.5 ± 10.5 72 ± 9.1 0.444 0.330 0.043*
Ao sinus (mm) 40.6 ± 4.5 42.4 ± 4.6 0.341 0.129 0.489
Ao asc (mm) 29.8 ± 4.8 33.7 ± 3.1 0.051 0.363 0.089
Ao arch (mm) 21.9 ± 3.6 25.9 ± 4.9 0.009* 0.293 0.087
Ao des (mm) 17 (16–18.5) 21 (18–23.3) 0.002* 0.622 <0.001*
Ao abd (mm) 16.1 ± 2.8 19.7 ± 3.6 0.002* 0.474 0.004*
LVEDD index (mm/m2) 25.7 ± 4.4 24.5 ± 5 0.441 −0.201 0.240
LVmass index (gr/m2) 80.9 ± 27.4 108 ± 44.5 0.026* 0.286 0.081
LVEF (%) 67.4 ± 8.1 72.2 ± 10.6 0.130 0.225 0.187
RVEDD index (mm/m2) 15.8 ± 2.6 15.3 ± 3 0.633 −0.286 0.113
TAPSE 21.1 ± 4.1 21.9 ± 4.1 0.569 0.197 0.243
E wave (cm/s) 74 ± 21.1 69 ± 18.1 0.451 −0.217 0.185
E/A ratio 1.7 ± 0.59 1.3 ± 0.4 0.047* −0.309 0.056
Em (cm/s) 9.3 ± 2.8 8.8 ± 2.1 0.576 −0.159 0.368
LA vol index (ml/m2) 23.4 ± 11.5 31.5 ± 18.4 0.111 0.174 0.302
NT‐proBNP (pg/ml) 66.5 (24.3–112.5) 83 (55–294) 0.119 0.113 0.443
(Continues)
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treatment procedure in our hospital. These patients experi-
enced subjective improvement of fatigue and quality of life. 
Their aortic sinus diameter at baseline was 43  mm for the 
male and 38 mm for the female patient and remained stable 
during the study period. The male patient experienced Afib 
2 years after initiation of treatment with nCPAP.
4 |  DISCUSSION
In previous studies, a relative high prevalence of OSA has 
been reported in patients with MFS. Although patients with 
MFS have higher cardiovascular risk than the general popu-
lation and additional risk factors could, in theory, further 
increase this risk, the relation between OSA and cardiovas-
cular features is still a matter of debate. In our study, we con-
firm a high prevalence of OSA (42.5%) in MFS. Although 
the mean BMI of our cohort was low, BMI was the strong-
est risk factor for OSA. In fact, we found that the preva-
lence of overweight was relatively high (27.5% overall and 
55.6% if ≥40 years). Although patients with OSA showed 
higher systolic blood pressure, larger distal aortic diameters, 
and higher prevalence of complex ventricular events, these 
differences were no longer significant after adjusting for 
confounding variables.
The prevalence of OSA in MFS patients found in our 
study is comparable with previous reports (Kohler et al., 
2009; Rybczynski et al., 2010). In the general population, 
OSA prevalence varies strongly depending on the studied 
group, and mainly the applied diagnostic technique and hy-
popnea scoring definition. Overall, the prevalence of OSA 
in the general population defined as an AHI  ≥  5, ranges 
between 9% and 38% (Senaratna et al., 2017). Therefore 
the prevalence in our cohort is at least comparable to the 
general population. Two earlier reports on MFS patients 
showed that in comparison to age‐ and sex‐matched con-
trols, patients with MFS had a significantly higher prev-
alence of OSA (32.8% vs. 11.5% in the study of Kohler 
and colleagues [Kohler et al., 2009] and 64% vs. 8% in the 
study of Cistulli and Sullivan [Cistulli & Sullivan, 1993]). 
In our cohort those patients accepting and declining PSG 
were very similar (as shown in Table S1), but differ in the 
ESS score. Although the ESS score was not high in the 
patients accepting PSG, it is possible that there is a bias 
and that this cohort may not be representative for the whole 
MFS population.
  AHI < 5 (n = 23) AHI ≥ 5 (n = 17) p‐valuea
Correlation coef-
ficient b p‐valuec
ECG and 24 hr‐Holter investigation
PR‐interval (ms) 153.2 ± 22.8 163.3 ± 25.1 0.210 0.144 0.388
QRS‐duration (ms) 96.6 ± 12.5 86.9 ± 23.7 0.106 −0.018 0.913
QTc time (ms) 419.1 ± 25.4 419,8 ± 17.4 0.925 0.029 0.865
Average HR (bpm) 65.7 ± 7.3 62.6 ± 17.7 0.457 0.038 0.823
Min HR (bpm) 46.1 ± 5.1 46.3 ± 5.1 0.936 −0.179 0.283
Max HR (bpm) 129.6 ± 23.8 114.9 ± 20.6 0.059 0.114 0.497
RMSSD (ms) 65 (51.5–82) 63 (35–91) 0.427 −0.136 0.430
SDNN (ms) 185 (138.5–199.5) 161 (119–178) 0.028* −0.366 0.026*
SVES/24 hr 5 (2–38) 14 (6–42) 0.442 0.100 0.549
VES/24 hr 6 (2–100) 42 (4–312) 0.137 0.266 0.094
VE (%) 8 (34.8) 7 (46.7) 0.346 0.119 0.464
Complex ventricular event (%) 3 (13) 8 (53.3) 0.011* 0.434 0.007*
Note: Data are mean ± standard deviation or median (interquartile range) when appropriate, except when otherwise indicated.
Abbreviations: Ao, aortic; AoRR, Aortic root replacement; ARB, Angiotensin Receptor Antagonist; BB, Beta‐blocker; BMI, Body mass index; DBP, Diastolic blood 
pressure; ECG, electrocardiogram; ESS, Epworth sleepiness scale; HR, Heart rate; LA, left atrium; LVEDD, Left ventricular end diastolic diameter; LVEF, Left 
ventricular ejection fraction; NT‐proBNP, N‐terminal prohormone of Brain Natriuretic Peptide; RMSSD, square root of the mean squared difference of successive 
NN intervals; RVEDD, Right ventricular end diastolic diameter; SBP, Systolic blood pressure; SDNN, standard deviation of the NN interval; SVES, Supraventricular 
extrasystole; VE, ventricular ectopy; VES, Ventricular extrasystole.
ap‐Value of univariate analysis. 
bSpearman for continuous variables and Phi for categoric variables. 
cp‐Value of correlation analysis. 
dMarfan systemic score: this is a scoring system which takes into consideration several characteristic features of MFS and assigns each of them a value between 1 and 
3, 3 being the most specific for the disease. A score of ≥7 is considered abnormal and in combination with aortic disease and/or ectopia lentis is diagnostic of MFS. 
eUse of BB alone or in combination with ARB. Three patients and 1 patient in the AHI < 5 and AHI ≥ 5 group respectively were taking Losartan in monotherapy. 
*Statistic significant at the p < 0.05 level. 
T A B L E  1  (Continued)
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The majority of the episodes of sleep apnea were 
obstructive; however some patients presented sporadic 
episodes of central apnea. Two patients presented a higher 
amount of central apnea with a total of 36 and 37 epi-
sodes respectively during the study. Central apnea has 
been associated with heart failure and Afib in non‐MFS 
patients (Naughton, 2016; Rowley & Badr, 2017). In the 
study of Rybczynski and colleagues a surprisingly high 
amount of central sleep apnea in their cohort was observed 
(almost half of the events were of the central type). OSA 
was also independently associated with Afib, lower left 
ventricular ejection fraction and higher levels of NT‐
ProBNP in this study. The two patients with central sleep 
apnea in our study had AoRR in the past and had moderate 
aortic valve regurgitation. However their left ventricular 
ejection fraction was in the lower range of normal (58%) 
and their NT‐proBNP level was not elevated. We therefore 
think that central apnea as a consequence of heart failure 
was not an issue in our patients. The only observation we 
could make, is that these two patients had low values of 
RMSSD and SDNN, two indexes of heart rate variabil-
ity, indicating a possible degree of autonomic dysfunc-
tion. Autonomic dysfunction has already been associated 
with chemoreceptor and baroreceptor alterations (Hakim, 
Gozal, & Gozal, 2012) and could possibly explain central 
sleep apnea in these patients. The study of autonomic dys-
function was beyond the scope of this study but may need 
further attention.
T A B L E  2  Regression models used to predict OSA
  Odds Ratio 95% CI p‐Value
BMI (per kg/m2) 1.353 1.109–1.651 0.003*
Age (per yr) 1.084 1.019–1.153 0.010*
MFS systemic scorea 0.820 0.671–1.003 0.053
Model 1 (BMI, Age, 
Sexb)
1.401 1.089–1.802 0.009*
Model 2 (BMI, Age, 
Sexb, Stop‐BANG)
1.4 1–1.8 0.025*
Abbreviations: BMI, Body Mass Index; MFS, Marfan syndrome; yr, year.
aMarfan systemic score is a scoring system which takes into consideration 
several characteristic features of MFS and assigns each of them a value between 
1–3, 3 being the most specific for the disease. A score of ≥7 is considered ab-
normal and in combination with aortic disease and/or ectopia lentis is diagnostic 
of MFS. 
bReference category: female. 
*Statistic significant at the level of p < 0.05. 
F I G U R E  3  Adjusted regression models to study the independent association between OSA and different cardiovascular features. Continuous 
outcome variables (systolic blood pressure and distal aortic diameters) were analyzed using linear regression and therefore the regression 
coefficient (β) is given. Categoric outcome variables (complex ventricular arrythmia) were analyzed using logistic regression and therefore the odds 
ratio (OR) is given. *Statistic significant at a value of p < 0.005. For linear regression confidence interval (CI) could not include the 0, for logistic 
regression the CI could not contain the 1. AHI, apnea–hypopnea index; BMI, body mass index; LVEDD, left ventricular end diastolic diameter; 
OSA, obstructive sleep apnea; SBP, systolic blood pressure
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Risk factors for OSA in non‐MFS subjects are male sex, 
age, and higher BMI (Senaratna et al., 2017; Tufik, Santos‐
Silva, Taddei, & Bittencourt, 2010). Although in our cohort 
the proportion of males with OSA was higher and those pa-
tients with OSA were significantly older, only BMI was in-
dependently associated with OSA (OR 1.4 per kg/m2, 95% 
IC 1.1–1.8, p = 0.009). In our clinical practice, we observed 
that a subgroup of MFS patients present visceral obesity at a 
young age while others develop this with age. Finding such 
a high percentage of overweight in our cohort (27.5% of 
the patients in the whole cohort and in 55.6% if >40 years) 
was slightly surprising, but not unexpected. In fact a previ-
ous report of Yetman and McCrindle (2010) in MFS patients 
aged 38 ± 13 years, found similar rates of overweight (36%). 
Although obese patients have the highest risk of OSA, the 
risk for patients with overweight (BMI 25–30 kg/m2) is still 
increased (OR 2.6, 95% IC 1.9–3.7) (Tufik et al., 2010) and 
therefore the realization that MFS patients also have over-
weight, especially in older ages is important. When consid-
ering a prediction model to identify patients at risk of OSA, 
the strongest model seems to include age, sex, and the STOP‐
Bang score next to the BMI. Although the STOP‐Bang score 
did not have a high sensitivity (47.1%), it had a high specific-
ity (90.5%), meaning that if positive, the probability for having 
OSA is high. The sensitivity and specificity of the ESS score 
were lower (35.5% and 85.7% respectively) and therefore 
we think that using the STOP‐Bang as screening tool could 
be more useful. We did not include measurements of facial 
features or airway collapsibility, as done in previous studies 
(Cistulli et al., 2001; Cistulli & Sullivan, 1995). We can there-
fore not exclude that these parameters need to be taken into 
consideration in a predictive model of OSA for MFS.
Controversy still exists regarding the association between 
OSA and cardiovascular risk in MFS. Although Kholer et 
al. showed a correlation between aortic root diameter and 
the AHI (Kohler et al., 2009) and higher incidence of aortic 
events (aortic surgery or dissection) in those MFS patients 
with OSA (Kohler et al., 2013), neither we nor Rybczynski 
and colleagues (Rybczynski et al., 2010), could confirm this 
association. Similar to our study, Rybczynski et al. found en-
larged diameters of the descending aorta associated with the 
AHI but this association was not significant after adjusting 
for age and BMI. Systolic blood pressure and proximal aor-
tic diameters did not correlate with the AHI in their study 
(Rybczynski et al., 2010).
In contrast to the general population, was the relationship 
between OSA and myocardial dysfunction and arrhythmia 
has been evaluated in several studies (Gottlieb et al., 2010; 
Holmqvist et al., 2015; Mehra et al., 2006; Sun, Shi, Li, & 
Chen, 2013), scarce data are available in MFS patients. Lower 
left ventricular function, higher levels of NT‐proBNP and 
higher frequency of Afib were associated with a higher AHI 
in the study of Rybczynski et al. (Rybczynski et al., 2010). 
We did not find any association between OSA and myocar-
dial dysfunction or Afib but saw a tendency in the incidence 
of Afib (three of the four patients with Afib had OSA).
Our study had some limitations and therefore some ques-
tions remain unanswered. (a) Although we were not able 
to show a higher cardiovascular risk in those MFS patients 
with OSA, our cohort might be too small and patients with 
AHI ≥ 15 might need to be considered separately in a mul-
ticenter study. (b) We did not consider subjective measures 
of “disease burden” such as quality of life or frame of mind. 
There is still controversy in the literature regarding the effect 
of OSA and its treatment on these matters (Batool‐Anwar et 
al., 2016; Coman, Borzan, Vesa, & Todea, 2016; Gaisl et al., 
2017; Jehan et al., 2017). We are not aware of specific tri-
als, studying the effect of CPAP and improvement of OSA 
in quality of life in patients with MFS. One study has been 
performed in patients with Ehlers Danlos syndrome (EDS), 
another connective tissue disorder, showing a beneficial effect 
(Guilleminault et al., 2013). Further study of quality of life 
and frame of mind in MFS patients needs more attention and 
might guide the decision on whether treatment is necessary 
or not. (c) At this point we have no longitudinal data on how 
OSA evolves in MFS. To study this, it would be, useful to 
repeat the PSG after a few years to test whether the number 
of events increases over time and to allow for a concrete rec-
ommendation on how to manage OSA in MFS patients. (d) 
Although the mean BMI was low, we observed a high preva-
lence of overweight in our cohort, especially in the older pa-
tients. Given the strong association between overweight and 
OSA, we hypothesize that maybe treating overweight could 
have, at least, similar effect on cardiovascular health as treat-
ing OSA. A randomized controlled trial in obese patients with 
moderate to severe apnea showed similar reductions in blood 
pressure between the groups treated with CPAP, weight loss 
and combination therapy (Chirinos et al., 2014). Studying 
the effect of overweight reduction in MFS on cardiovascular 
health in general and on OSA in particular, could be useful.
In conclusion, as in the general population, OSA has a 
high occurrence in MFS patients and is strongly associated 
with BMI. Until now no significant association between 
OSA and cardiovascular outcome in MFS can be stablished. 
However, ours and previous studies may be underpowered 
and collaborative efforts are still necessary to answer some 
important questions. Another relevant aspect is that with in-
creasing survival and aging, the classical view of MFS pa-
tients as long and slender seems to shift and new risk factors 
among which sleep apnea and overweight may need to be 
targeted.
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